Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients

Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy

Disease Types: Breast

Available at: Roanoke

Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions

For More Information:

https://clinicaltrials.gov/study/NCT05068726?term=Fluoroestradiol%20F18%20PET%2FCT%20in%20Metastatic%20Breast%20Cancer%20Patients%20with%20ER-Positive%20and%20HER2-Negative%20Primary%20Lesions&rank=1